The employee received non-qualified stock options for 13,500 shares at an exercise price of $8.95 per share, matching the Nasdaq closing price on September 19. These options vest over a four-year period, with 25% becoming exercisable on the first anniversary of the grant and the remainder vesting in 36 monthly installments. Additionally, the individual was granted 6,750 restricted stock units, which follow a similar four-year vesting schedule, with 25% vesting after one year and the remainder split across three subsequent annual installments.

These awards were approved by the Human Capital Management Committee of the Board of Directors, a body comprised entirely of independent directors, in compliance with Nasdaq Listing Rule 5635(c)(4). The grants serve as a material employment inducement as the company advances its pipeline, including the ATR 1072 clinical program for PRKAG2 syndrome.